Biomaterial Database

Pancreatic enzyme supplementation in cystic fibrosis. 1993

C M Hill, and C J Rolles, and P Keegan, and R A Chand

UI	MeSH Term	Description	Entries
D007223	Infant	A child between 1 and 23 months of age.	Infants
D008297	Male		Males
D010194	Pancreatin	A mammalian pancreatic extract composed of enzymes with protease, amylase and lipase activities. It is used as a digestant in pancreatic malfunction.	Panteric,Panzytrat
D002214	Capsules	Hard or soft soluble containers used for the oral administration of medicine.	Capsule,Microcapsule,Microcapsules
D002648	Child	A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL.	Children
D002675	Child, Preschool	A child between the ages of 2 and 5.	Children, Preschool,Preschool Child,Preschool Children
D003550	Cystic Fibrosis	An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.	Mucoviscidosis,Cystic Fibrosis of Pancreas,Fibrocystic Disease of Pancreas,Pancreatic Cystic Fibrosis,Pulmonary Cystic Fibrosis,Cystic Fibrosis, Pancreatic,Cystic Fibrosis, Pulmonary,Fibrosis, Cystic,Pancreas Fibrocystic Disease,Pancreas Fibrocystic Diseases
D005260	Female		Females
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284	Administration, Oral	The giving of drugs, chemicals, or other substances by mouth.	Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

C M Hill, and C J Rolles, and P Keegan, and R A Chand

[Cystic fibrosis: current therapy. Pancreatic enzyme supplementation].

January 2000, Schweizerische medizinische Wochenschrift. Supplementum,

C M Hill, and C J Rolles, and P Keegan, and R A Chand

Adherence to pancreatic enzyme supplementation in adolescents with cystic fibrosis.

January 2012, Canadian journal of dietetic practice and research : a publication of Dietitians of Canada = Revue canadienne de la pratique et de la recherche en dietetique : une publication des Dietetistes du Canada,

C M Hill, and C J Rolles, and P Keegan, and R A Chand

Maintenance of growth in cystic fibrosis despite reduction in pancreatic enzyme supplementation.

April 1998, Archives of disease in childhood,

C M Hill, and C J Rolles, and P Keegan, and R A Chand

13Carbon mixed triglyceride breath test and pancreatic enzyme supplementation in cystic fibrosis.

April 1997, Archives of disease in childhood,

C M Hill, and C J Rolles, and P Keegan, and R A Chand

Pancreatic enzyme supplementation in cystic fibrosis patients before and after fibrosing colonopathy.

January 1998, Journal of pediatric gastroenterology and nutrition,

C M Hill, and C J Rolles, and P Keegan, and R A Chand

Pancreatic enzyme therapy in cystic fibrosis.

December 2008, Expert review of respiratory medicine,